Australian Industry Signs Deal To Fund Access To Innovative New Drugs
Plans Include More Horizon Scanning Of New Therapies In Pipeline
Hot on the heels of Australia’s plan to overhaul the National Medicines Policy comes a new deal with the pharmaceutical industry to make new drugs available as soon as possible after approval and get patients more closely involved in reimbursement processes.
You may also be interested in...
Drug industry group Medicines Australia says that the review of the health technology assessment system must ensure that the real impact and benefits of new products for patients are taken into account in reimbursement decisions. Other areas to be explored include the use of real-world data and managing clinical and economic uncertainty.
The Australian government has committed to cutting co-payments for medicines listed on its pharmaceutical benefits scheme by 30%, a move which has been praised by the country’s Generic and Biosimilar Medicines Association.
Australia’s health department has issued guidance giving more details of the requirement to hold minimum levels of stocks of specified medicines from mid-2023.